206 related articles for article (PubMed ID: 24207089)
1. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology.
Zaakook M; Ayoub M; Sinna EA; El-Sheikh S
J Egypt Natl Canc Inst; 2013 Dec; 25(4):173-80. PubMed ID: 24207089
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
4. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
Ligato S; Mandich D; Cartun RW
Mod Pathol; 2008 May; 21(5):626-31. PubMed ID: 18264086
[TBL] [Abstract][Full Text] [Related]
5. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
[TBL] [Abstract][Full Text] [Related]
7. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
8. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
McKnight R; Nassar A; Cohen C; Siddiqui MT
Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
10. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
13. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
14. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.
Bakheet AMH; Zhao C; Chen JN; Zhang JY; Huang JT; Du Y; Gong LP; Bi YH; Shao CK
Hepatol Int; 2020 Jan; 14(1):96-104. PubMed ID: 31832976
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
16. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
19. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
